{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:55:41Z","timestamp":1793318141452,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["Tifft ZIAHG200409"],"award-info":[{"award-number":["Tifft ZIAHG200409"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Clinical trials for rare diseases pose unique challenges warranting alternative approaches in demonstrating treatment efficacy. Such trials face challenges including small patient populations, variable onset of symptoms and rate of disease progression, and ethical considerations, particularly in neurodegenerative diseases. In this study, we present the retrospective clinical global impression (RCGI) severity and change (RCGI-S\/C) scale on 27 patients with GM1 gangliosidosis, a post hoc clinician-rated outcome measure to evaluate natural history study participants as historical controls for comparisons with treated patients in a clinical trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a systematic chart review of 27 GM1 gangliosidosis natural history participants across 95 total visits. RCGI-S was assessed at the first visit and rated 1 (normal) to 7 (among the most extremely ill). Each subsequent follow-up was rated on the RCGI-C scale from 1 (very much improved) to 7 (very much worse). We demonstrate scoring guidelines of both scales with examples and justifications for this pilot in GM1 gangliosidosis natural history participants. The convergent validity of the RCGI scales was explored through correlations with magnetic resonance imaging (MRI) and the Vineland Adaptive Behavioral Scales.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found strong association between the RCGI-S scores with gray matter volume (r(14)\u2009=\u2009\u22120.81; 95% CI [\u22120.93, \u22120.51], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and RCGI-C scores significantly correlated with increases in ventricular volume (\u03c7<jats:sup>2<\/jats:sup>(1)\u2009=\u200918.6, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Baseline RCGI-S scores also strongly correlated with Vineland adaptive behavioral composite scores taken at the same visit (r(14)\u2009=\u2009\u22120.72; 95% CI [\u22120.93, \u22120.17], <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>RCGI-S\/C scales, which use the clinical evaluation to assess the severity of disease of each patient visit over time, were consolidated into a single quantitative metric in this study. Longitudinal RCGI-C scores allowed us to quantify disease progression in our late-infantile and juvenile GM1 patients. We suggest that the retrospective CGI may be an important tool in evaluating historical data for comparison with changes in disease progression\/mitigation following therapeutic interventions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03614-6","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:11:58Z","timestamp":1741954318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Retrospective assessment of clinical global impression of severity and change in GM1 gangliosidosis: a tool to score natural history data in rare disease cohorts"],"prefix":"10.1186","volume":"20","author":[{"given":"Connor J.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zaragoza Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Vezina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precilla","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Gahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Tifft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-7401","authenticated-orcid":false,"given":"Maria T.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"9","key":"3614_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142\u201350.","journal-title":"J Child Neurol"},{"issue":"10\u201312","key":"3614_CR2","first-page":"15","volume":"18","author":"J Busner","year":"2021","unstructured":"Busner J, Pandina G, Domingo S, Berger A-K, Acosta MT, Fisseha N, Horrigan J, Ivkovic J, Jacobson W, Revicki D, et al. Clinician-and patient-reported endpoints in cns orphan drug clinical trials: Isctm position paper on best practices for endpoint selection, validation, training, and standardization. Innov Clin Neurosci. 2021;18(10\u201312):15.","journal-title":"Innov Clin Neurosci"},{"issue":"2","key":"3614_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"issue":"1\u20133","key":"3614_CR4","first-page":"52","volume":"21","author":"GJ Pandina","year":"2024","unstructured":"Pandina GJ, Busner J, Kempf L, Fallon J, Alphs LD, Acosta MT, Berger AK, Day S, Dunn J, Villalta-Gil V, Grabb MC, Horrigan JP, Jacobson W, Kando JC, Macek TA, Singh MK, Stanford AD, Domingo SZ. Ensuring stakeholder feedback in the design and conduct of clinical trials for rare diseases: ISCTM position paper of the orphan disease working group. Innov Clin Neurosci. 2024;21(1\u20133):52\u201360.","journal-title":"Innov Clin Neurosci"},{"key":"3614_CR5","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/jcph.2134","volume":"62","author":"J Liu","year":"2022","unstructured":"Liu J, Barrett JS, Leonardi ET, Lee L, Roychoudhury S, Chen Y, Trifillis P. Natural history and real-world data in rare diseases: applications, limitations, and future perspectives. J Clin Pharmacol. 2022;62:S38\u201355.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3614_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ajmg.a.38413","volume":"176","author":"L Kempf","year":"2018","unstructured":"Kempf L, Goldsmith JC, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet A. 2018;176(4):773\u201383.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"3614_CR7","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/s41591-023-02333-4","volume":"29","author":"M May","year":"2023","unstructured":"May M. Rare-disease researchers pioneer a unique approach to clinical trials. Nat Med. 2023;29(8):1884\u20136.","journal-title":"Nat Med"},{"key":"3614_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.734878","volume":"12","author":"E-R Nicoli","year":"2021","unstructured":"Nicoli E-R, Annunziata I, d\u2019Azzo A, Platt FM, Tifft CJ, Stepien KM. Gm1 gangliosidosis\u2014a mini-review. Front Genet. 2021;12: 734878.","journal-title":"Front Genet"},{"key":"3614_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/TACG.S206076","volume":"14","author":"AK Rha","year":"2021","unstructured":"Rha AK, Maguire AS, Martin DR. Gm1 gangliosidosis: mechanisms and management. Appl Clin Genet. 2021;14:209\u201333.","journal-title":"Appl Clin Genet"},{"issue":"2","key":"3614_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","volume":"121","author":"JRJ Utz","year":"2017","unstructured":"Utz JRJ, Kim S, King K, Ziegler R, Schema L, Redtree ES, Whitley CB. Infantile gangliosidoses: mapping a timeline of clinical changes. Mol Genet Metab. 2017;121(2):170\u20139.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3614_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","volume":"94","author":"N Brunetti-Pierri","year":"2008","unstructured":"Brunetti-Pierri N, Scaglia F. Gm1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008;94(4):391\u20136.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3614_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ymgme.2019.12.012","volume":"129","author":"FM Lang","year":"2020","unstructured":"Lang FM, Korner P, Harnett M, Karunakara A, Tifft CJ. The natural history of type 1 infantile gm1 gangliosidosis: a literature-based meta-analysis. Mol Genet Metab. 2020;129(3):228\u201335.","journal-title":"Mol Genet Metab"},{"key":"3614_CR13","doi-asserted-by":"publisher","unstructured":"Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27. https:\/\/doi.org\/10.1038\/s41572-018-0025-4. Erratum in: Nat Rev Dis Primers. 2018 Oct 18;4(1):36. Erratum in: Nat Rev Dis Primers. 2019 May 17;5(1):34. PMID: 30275469.","DOI":"10.1038\/s41572-018-0025-4"},{"issue":"2","key":"3614_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ymgme.2017.12.432","volume":"123","author":"I Nestrasil","year":"2018","unstructured":"Nestrasil I, Ahmed A, Utz JM, Rudser K, Whitley CB, Jarnes-Utz JR. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: volumetric quantitative mri study. Mol Genet Metab. 2018;123(2):97\u2013104.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"3614_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0387-7604(99)00073-X","volume":"21","author":"MA Al-Essa","year":"1999","unstructured":"Al-Essa MA, Bakheet SM, Patay ZJ, Nounou RM, Ozand PT. Cerebral fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (fdg pet), mri, and clinical observations in a patient with infantile gm1 gangliosidosis. Brain Develop. 1999;21(8):559\u201362.","journal-title":"Brain Develop"},{"key":"3614_CR16","doi-asserted-by":"publisher","first-page":"104627","DOI":"10.1016\/j.ebiom.2023.104627","volume":"92","author":"P Kell","year":"2023","unstructured":"Kell P, Sidhu R, Qian M, Mishra S, Nicoli E-R, D\u2019Souza P, Tifft CJ, Gross AL, Gray-Edwards HL, Martin DR, et al. A pentasaccharide for monitoring pharmacodynamic response to gene therapy in gm1 gangliosidosis. EBioMedicine. 2023;92:104627.","journal-title":"EBioMedicine"},{"issue":"7","key":"3614_CR17","doi-asserted-by":"publisher","first-page":"101144","DOI":"10.1016\/j.gim.2024.101144","volume":"26","author":"P D\u2019Souza","year":"2024","unstructured":"D\u2019Souza P, Farmer C, Johnston JM, Han ST, Adams D, Hartman AL, Zein W, Huryn LA, Solomon B, King K, Jordan CP, Myles J, Nicoli ER, Rothermel CE, Algarin YM, Huang R, Quimby R, Zainab M, Bowden S, Crowell A, Buckley A, Brewer C, Regier DS, Brooks BP, Acosta MT, Baker EH, V\u00e9zina G, Thurm A, Tifft CJ. GM1 gangliosidosis type II: results of a 10-year prospective study. Genet Med: Off J Am Coll Med Genet. 2024;26(7):101144.","journal-title":"Genet Med: Off J Am Coll Med Genet"},{"issue":"1","key":"3614_CR18","doi-asserted-by":"publisher","first-page":"e207958","DOI":"10.1212\/WNL.0000000000207958","volume":"102","author":"AT Berg","year":"2024","unstructured":"Berg AT, Ludwig NN, Wojnaroski M, Chapman CAT, Hommer R, Conecker G, Hecker JZ, Downs J. FDA patient-focused drug development guidances: considerations for trial readiness in rare developmental and epileptic encephalopathies. Neurology. 2024;102(1):e207958. https:\/\/doi.org\/10.1212\/WNL.0000000000207958.","journal-title":"Neurology"},{"issue":"7","key":"3614_CR19","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28.","journal-title":"Psychiatry (Edgmont)"},{"key":"3614_CR20","doi-asserted-by":"crossref","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, 1976.","DOI":"10.1037\/e591322011-001"},{"issue":"7","key":"3614_CR21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jval.2021.01.005","volume":"24","author":"A Gnanasakthy","year":"2021","unstructured":"Gnanasakthy A, Barrett A, Norcross L, D\u2019Alessio D, Romano CD. Use of patient and investigator global impression scales: a review of food and drug administration\u2013approved labeling, 2009 to 2019. Value in Health. 2021;24(7):1016\u201323.","journal-title":"Value in Health"},{"issue":"1","key":"3614_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11689-020-09349-8","volume":"13","author":"A Kolevzon","year":"2021","unstructured":"Kolevzon A, Ventola P, Keary CJ, Heimer G, Neul JL, Adera M, Jaeger J. Development of an adapted clinical global impression scale for use in angelman syndrome. J Neurodev Disord. 2021;13(1):1\u201313.","journal-title":"J Neurodev Disord"},{"issue":"3","key":"3614_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ajmg.a.37468","volume":"170","author":"DS Regier","year":"2016","unstructured":"Regier DS, Kwon HJ, Johnston J, Golas G, Yang S, Wiggs E, Latour Y, Thomas S, Portner C, Adams D, Vezina G, Baker EH, Tifft CJ. MRI\/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis. Am J Med Genet A. 2016;170(3):634\u201344. https:\/\/doi.org\/10.1002\/ajmg.a.37468.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"3614_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ymgme.2017.12.432","volume":"123","author":"I Nestrasil","year":"2018","unstructured":"Nestrasil I, Ahmed A, Utz JM, Rudser K, Whitley CB, Jarnes-Utz JR. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: volumetric quantitative MRI study. Mol Genet Metab. 2018;123(2):97\u2013104. https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.432.","journal-title":"Mol Genet Metab"},{"key":"3614_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13312-015-0593-2","volume":"52","author":"M Tuteja","year":"2015","unstructured":"Tuteja M, Bidchol AM, Girisha KM, et al. White matter changes in GM1 gangliosidosis. Indian Pediatr. 2015;52:155\u20136. https:\/\/doi.org\/10.1007\/s13312-015-0593-2.","journal-title":"Indian Pediatr"},{"issue":"2","key":"3614_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00004728-199403000-00005","volume":"18","author":"DL Collins","year":"1994","unstructured":"Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3d intersubject registration of mr volumetric data in standardized talairach space. J Comput Assist Tomogr. 1994;18(2):192\u2013205.","journal-title":"J Comput Assist Tomogr"},{"issue":"2","key":"3614_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/nimg.1998.0395","volume":"9","author":"AM Dale","year":"1999","unstructured":"Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis: I. segmentation and surface reconstruction. Neuroimage. 1999;9(2):179\u201394.","journal-title":"Neuroimage"},{"issue":"2","key":"3614_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/nimg.1998.0396","volume":"9","author":"B Fischl","year":"1999","unstructured":"Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis: Ii: inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999;9(2):195\u2013207.","journal-title":"Neuroimage"},{"issue":"4","key":"3614_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4","volume":"8","author":"B Fischl","year":"1999","unstructured":"Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp. 1999;8(4):272\u201384.","journal-title":"Hum Brain Mapp"},{"issue":"20","key":"3614_CR30","doi-asserted-by":"publisher","first-page":"11050","DOI":"10.1073\/pnas.200033797","volume":"97","author":"B Fischl","year":"2000","unstructured":"Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci. 2000;97(20):11050\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"3614_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1109\/42.906426","volume":"20","author":"B Fischl","year":"2001","unstructured":"Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20(1):70\u201380.","journal-title":"IEEE Trans Med Imaging"},{"key":"3614_CR32","unstructured":"\u201cNon-uniform intensity correction,\u201d http:\/\/www.bic.mni.mcgill.ca\/software\/N3\/node6.html."},{"issue":"3","key":"3614_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","volume":"33","author":"B Fischl","year":"2002","unstructured":"Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, Van Der Kouwe A, Killiany R, Kennedy D, Klaveness S, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341\u201355.","journal-title":"Neuron"},{"issue":"1","key":"3614_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/cercor\/bhg087","volume":"14","author":"B Fischl","year":"2004","unstructured":"Fischl B, Van Der Kouwe A, Destrieux C, Halgren E, S\u00e9gonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14(1):11\u201322.","journal-title":"Cereb Cortex"},{"key":"3614_CR35","volume-title":"Vineland adaptive behavior scales","author":"SS Sparrow","year":"2005","unstructured":"Sparrow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales. 2nd ed. Minnesota: Pearson Assessments; 2005.","edition":"2"},{"key":"3614_CR36","unstructured":"Sparrow SS, Cicchetti DV, Saulnier CA. Vineland-3: Vineland adaptive behavior scales. PsychCorp; 2016."},{"issue":"5","key":"3614_CR37","first-page":"328","volume":"170","author":"RB Dessau","year":"2008","unstructured":"Dessau RB, Pipper CB. R--en programpakke til statistisk databehandling og grafik [\u201cR\u201d\u2013project for statistical computing]. Ugeskr Laeger. 2008;170(5):328\u201330.","journal-title":"Ugeskr Laeger"},{"issue":"1","key":"3614_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00a8achler M, Bolker B, Walker S. Fitting linear mixed effects models using lme4. J Stat Softw. 2015;67(1):1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01.","journal-title":"J Stat Softw"},{"key":"3614_CR39","doi-asserted-by":"publisher","unstructured":"Winter B, Linear models and linear mixed effects models in R with linguistic applications\u201d, 2013. https:\/\/doi.org\/10.48550\/arXiv.1308.5499.","DOI":"10.48550\/arXiv.1308.5499"},{"issue":"14","key":"3614_CR40","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1002\/hbm.25968","volume":"43","author":"N Mittal","year":"2022","unstructured":"Mittal N, Thakkar B, Hodges CB, Lewis C, Cho Y, Hadimani RL, Peterson CL. Effect of neuroanatomy on corticomotor excitability during and after transcranial magnetic stimulation and intermittent theta burst stimulation. Hum Brain Mapp. 2022;43(14):4492\u2013507.","journal-title":"Hum Brain Mapp"},{"key":"3614_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euroneuro.2024.02.009","volume":"83","author":"S Zaragoza Domingo","year":"2024","unstructured":"Zaragoza Domingo S, Alonso J, Ferrer M, Acosta MT, Alphs L, Annas P, Balabanov P, Berger AK, Bishop KI, Butlen-Ducuing F, Dorffner G, Edgar C, de Gracia Blanco M, Harel B, Harrison J, Horan WP, Jaeger J, Kottner J, Pinkham A, Tinoco D, Yavorsky C. Methods for neuroscience drug development: guidance on standardization of the process for defining clinical outcome strategies in clinical trials. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2024;83:32\u201342. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.02.009.","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"issue":"6","key":"3614_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jpain.2015.02.007","volume":"16","author":"W Scott","year":"2015","unstructured":"Scott W, McCracken LM. Patients\u2019 impression of change following treatment for chronic pain: Global, specific, a single dimension, or many? J Pain. 2015;16(6):518\u201326. https:\/\/doi.org\/10.1016\/j.jpain.2015.02.007.","journal-title":"J Pain"},{"issue":"10\u201312","key":"3614_CR43","first-page":"15","volume":"18","author":"J Busner","year":"2021","unstructured":"Busner J, Pandina G, Domingo S, Berger AK, Acosta MT, Fisseha N, Horrigan J, Ivkovic J, Jacobson W, Revicki D, Villalta-Gil V. Clinician- and patient-reported endpoints in CNS orphan drug clinical trials: ISCTM position paper on best practices for endpoint selection, validation, training, and standardization. Innov Clin Neurosci. 2021;18(10\u201312):15\u201322.","journal-title":"Innov Clin Neurosci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03614-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:12:02Z","timestamp":1741954322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03614-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03614-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The NIH Institutional Review Board approved this protocol (02-HG-0107). Informed consent was completed with parents or legal guardians of the patients. All participants were assessed for their ability to provide assent; none were deemed capable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}